JP7236543B2 - Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム - Google Patents

Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム Download PDF

Info

Publication number
JP7236543B2
JP7236543B2 JP2021536205A JP2021536205A JP7236543B2 JP 7236543 B2 JP7236543 B2 JP 7236543B2 JP 2021536205 A JP2021536205 A JP 2021536205A JP 2021536205 A JP2021536205 A JP 2021536205A JP 7236543 B2 JP7236543 B2 JP 7236543B2
Authority
JP
Japan
Prior art keywords
hla
peptide
drb1
class
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021536205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518355A (ja
JP2022518355A5 (https=
Inventor
マイケル スティーブン ルーニー，
ジェニファー グレイス アベリン，
ドミニク バーセルミ，
ロバート カメン，
Original Assignee
ビオンテック ユーエス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビオンテック ユーエス インコーポレイテッド filed Critical ビオンテック ユーエス インコーポレイテッド
Publication of JP2022518355A publication Critical patent/JP2022518355A/ja
Publication of JP2022518355A5 publication Critical patent/JP2022518355A5/ja
Priority to JP2023028268A priority Critical patent/JP7531009B2/ja
Application granted granted Critical
Publication of JP7236543B2 publication Critical patent/JP7236543B2/ja
Priority to JP2024122210A priority patent/JP2024164839A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/0464—Convolutional networks [CNN, ConvNet]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Databases & Information Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Signal Processing (AREA)
  • Biomedical Technology (AREA)
JP2021536205A 2018-12-21 2019-12-20 Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム Active JP7236543B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023028268A JP7531009B2 (ja) 2018-12-21 2023-02-27 Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム
JP2024122210A JP2024164839A (ja) 2018-12-21 2024-07-29 Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862783914P 2018-12-21 2018-12-21
US62/783,914 2018-12-21
US201962826827P 2019-03-29 2019-03-29
US62/826,827 2019-03-29
US201962855379P 2019-05-31 2019-05-31
US62/855,379 2019-05-31
US201962891101P 2019-08-23 2019-08-23
US62/891,101 2019-08-23
PCT/US2019/068084 WO2020132586A1 (en) 2018-12-21 2019-12-20 Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023028268A Division JP7531009B2 (ja) 2018-12-21 2023-02-27 Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム

Publications (3)

Publication Number Publication Date
JP2022518355A JP2022518355A (ja) 2022-03-15
JP2022518355A5 JP2022518355A5 (https=) 2022-12-28
JP7236543B2 true JP7236543B2 (ja) 2023-03-09

Family

ID=71101917

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021536205A Active JP7236543B2 (ja) 2018-12-21 2019-12-20 Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム
JP2023028268A Active JP7531009B2 (ja) 2018-12-21 2023-02-27 Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム
JP2024122210A Pending JP2024164839A (ja) 2018-12-21 2024-07-29 Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023028268A Active JP7531009B2 (ja) 2018-12-21 2023-02-27 Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム
JP2024122210A Pending JP2024164839A (ja) 2018-12-21 2024-07-29 Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム

Country Status (13)

Country Link
US (2) US11183272B2 (https=)
EP (1) EP3899954A4 (https=)
JP (3) JP7236543B2 (https=)
KR (2) KR20240091046A (https=)
CN (2) CN113474840B (https=)
AU (1) AU2019404547B2 (https=)
BR (1) BR112021012278A2 (https=)
CA (1) CA3124457A1 (https=)
IL (1) IL284195A (https=)
MX (1) MX2021007556A (https=)
PH (1) PH12021551485A1 (https=)
SG (1) SG11202106678PA (https=)
WO (1) WO2020132586A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4414990A3 (en) 2013-01-17 2024-11-06 Personalis, Inc. Methods and systems for genetic analysis
US10125399B2 (en) 2014-10-30 2018-11-13 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
AU2016341309A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
US11965892B2 (en) * 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
US11176429B2 (en) * 2019-05-13 2021-11-16 International Business Machines Corporation Counter rare training date for artificial intelligence
JP7579812B2 (ja) 2019-05-31 2024-11-08 アイバイオ， インク． メソスケールペプチドを操作するための機械学習ベースの装置およびそのための方法およびシステム
JP7470787B2 (ja) 2019-11-05 2024-04-18 パーソナリス，インコーポレイティド 単一試料からの腫瘍純度の推定
US11049590B1 (en) 2020-02-12 2021-06-29 Peptilogics, Inc. Artificial intelligence engine architecture for generating candidate drugs
CA3179113A1 (en) * 2020-06-03 2021-12-09 Paul Holzer Selection and monitoring methods for xenotransplantation
EP4168569A4 (en) * 2020-06-18 2024-08-07 Personalis, Inc. Machine-learning techniques for predicting surface-presenting peptides
WO2022046895A2 (en) * 2020-08-25 2022-03-03 Genentech, Inc. Assays and reagents for characterization of mhci peptide binding
US20230326544A1 (en) * 2020-08-28 2023-10-12 Immunitybio, Inc. Computerized Tool For Prediction of Proteasomal Cleavage
CN116802738A (zh) * 2020-11-06 2023-09-22 亚马逊科技公司 为个体化癌症疫苗选择新抗原
US11403316B2 (en) 2020-11-23 2022-08-02 Peptilogics, Inc. Generating enhanced graphical user interfaces for presentation of anti-infective design spaces for selecting drug candidates
WO2022119863A1 (en) * 2020-12-01 2022-06-09 Rubryc Therapeutics, Inc. Generalized scaffolds for polypeptide display and uses thereof
CN116583903A (zh) * 2020-12-09 2023-08-11 上海瑞宏迪医药有限公司 基于机器学习的肽免疫原性预测、鉴别系统及方法
MX2023011119A (es) * 2021-03-25 2023-10-03 Genentech Inc Uso de redes neuronales para predecir inmunogenicidad de peptidos.
KR102769935B1 (ko) * 2021-03-30 2025-02-19 한국과학기술원 펩타이드-mhc에 대한 t 세포 활성의 예측 방법 및 분석장치
US11512345B1 (en) 2021-05-07 2022-11-29 Peptilogics, Inc. Methods and apparatuses for generating peptides by synthesizing a portion of a design space to identify peptides having non-canonical amino acids
CN113724787B (zh) * 2021-07-28 2024-05-03 扬州大学 一种基于核心-附件结构的蛋白质复合物识别方法
US12518851B2 (en) * 2021-09-07 2026-01-06 Nec Corporation Binding peptide generation for MHC class I proteins with deep reinforcement learning for immunotherapy decision making
WO2023059654A1 (en) 2021-10-05 2023-04-13 Personalis, Inc. Customized assays for personalized cancer monitoring
CN113807468B (zh) * 2021-10-15 2022-05-27 南京澄实生物科技有限公司 基于多模态深度编码的hla抗原呈递预测方法和系统
CN113936748B (zh) * 2021-11-17 2024-08-20 西安电子科技大学 基于集成学习的分子识别特征功能预测方法
CN114446385B (zh) * 2022-01-29 2024-08-13 杭州纽安津生物科技有限公司 Hla ii型分子与多肽的亲和力预测模型的获取方法及装置
US20250299771A1 (en) * 2022-02-22 2025-09-25 The Children's Hospital Of Philadelphia Systems and methods for generating chimeric major histocompatibility complex (mhc) molecules with desired peptide-binding specificities
WO2023192337A1 (en) * 2022-03-29 2023-10-05 Ahead Medicine Corp Methods and devices of processing cytometric data
CN114925743A (zh) * 2022-04-13 2022-08-19 国网上海市电力公司 一种用于变压器故障特征提取的降维方法
EP4526334A2 (en) * 2022-05-19 2025-03-26 BioNTech US Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
WO2024015892A1 (en) * 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
CN114913939B (zh) * 2022-07-19 2022-11-15 北京科技大学 高通量平台和机器学习优化的药物组合设计方法及装置
USD1117222S1 (en) * 2022-08-11 2026-03-10 Healthpartners Institute Display screen with graphical user interface
US20260120799A1 (en) * 2022-08-12 2026-04-30 Biontech Us Inc. Methods and systems for prediction of hla epitopes
CN115331728B (zh) * 2022-08-12 2023-06-30 杭州力文所生物科技有限公司 一种稳定折叠的富含二硫键的多肽设计方法及其电子设备
CN115333735B (zh) * 2022-10-11 2023-03-14 浙江御安信息技术有限公司 一种数据的安全传输方法
WO2024115638A1 (en) 2022-12-01 2024-06-06 Immunewatch Bv Method to evaluate the conspicuousness of an epitope towards the repertoire of t-cell receptors
WO2024192143A1 (en) * 2023-03-13 2024-09-19 Gritstone Bio, Inc. Epitope prediction via a learned genotype network across class ii mhc alleles
WO2024194208A1 (en) * 2023-03-17 2024-09-26 Achilles Therapeutics Uk Limited Prediction of immunogenicity
CN116597903A (zh) * 2023-05-26 2023-08-15 四川芸释新医学检验实验室有限公司 人源TCR/HLA-I/Peptide三元复合物交互识别预测方法及系统
CN116469457B (zh) * 2023-06-14 2023-10-13 普瑞基准科技（北京）有限公司 Mhc与抗原多肽结合、呈递及免疫原性的预测模型训练方法和装置
WO2025128525A1 (en) * 2023-12-11 2025-06-19 Research Development Foundation System and method for predicting microproteins
WO2025125528A1 (en) * 2023-12-14 2025-06-19 Miltenyi Biotec B.V. & Co. KG Multiplex mhc peptide binding and t cell detection method / quantifiable multiplex mhc binding assay
CN118248214A (zh) * 2024-02-01 2024-06-25 南方海洋科学与工程广东省实验室(珠海) 一种高置信的肠道菌群单氨基酸突变鉴定方法及其应用
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025213105A1 (en) * 2024-04-04 2025-10-09 Biontech Us Inc. Methods for identifying t-cell receptor (tcr) sequences
CN118571322B (zh) * 2024-05-21 2025-07-29 天津大学 蛋白序列分析方法、装置、设备、介质和产品

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090130134A1 (en) 2005-02-07 2009-05-21 Veronique Pancre T CD4+ Epitopes of Type I and II Latency Antigens of the Epstein-Barr Virus, Which Can Be Recognized by the majority of individuals in the caucasian populations and applications thereof
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
US20170212984A1 (en) 2015-12-16 2017-07-27 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
JP2020518083A (ja) 2017-03-31 2020-06-18 ヤン、ペイ−ジア 免疫原性がん特異的エピトープのためのランク付けシステム

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126A (en) 1847-05-22 Cast-iron cab-wheel
US170A (en) 1837-04-20 Improvement in concentrating-furnaces for smelting iron ores by the use of anthracite
US5912A (en) 1848-11-07 Lamp-wicks
US132A (en) 1837-02-25 Improvement in propelling machinery by magnetism and electro-magnetism
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
WO1988000970A2 (en) 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US6277558B1 (en) 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
JP3029135B2 (ja) 1991-04-23 2000-04-04 キヤノン株式会社 文字処理装置及び方法
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
US5874239A (en) 1993-07-30 1999-02-23 Affymax Technologies N.V. Biotinylation of proteins
EP0726941B1 (en) 1993-08-06 2002-04-03 Epimmune Inc. Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
CA2214649C (en) 1995-03-08 2007-06-12 Zeling Cai Antigen presenting system and methods for activation of t-cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JPH11511376A (ja) 1996-03-13 1999-10-05 アナロジック コーポレーション コンピュータ・トモグラフィの自己校正リング抑制フィルタ
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
US7255862B1 (en) 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
CA2278847A1 (en) 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
ATE466948T1 (de) 1997-03-11 2010-05-15 Univ Minnesota Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
WO1999014354A1 (en) 1997-09-19 1999-03-25 The Trustees Of The University Of The Pennsylvania Methods and vector constructs useful for production of recombinant aav
EP1015619A1 (en) 1997-09-19 2000-07-05 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
DK1180159T3 (da) 1999-05-28 2008-11-17 Targeted Genetics Corp Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
US6955808B2 (en) 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
GB0024550D0 (https=) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
NZ526489A (en) 2000-12-15 2007-07-27 Balwinder Singh Aulakh An in vivo method for producing female offsprings in mammals using a material comprising acetic acid
GB0202334D0 (en) 2001-04-05 2002-03-20 Nextgen Sciences Ltd Protein analysis
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
AU2005219876A1 (en) * 2004-03-01 2005-09-15 Peptimmune, Inc. Methods and compositions for treatment of autoimmune diseases
JP5191729B2 (ja) 2004-03-11 2013-05-08 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
AU2005246073B2 (en) 2004-05-19 2010-10-28 Adaptimmune Limited Method of improving T cell receptors
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
MX2007010008A (es) 2005-02-16 2008-01-18 Lentigen Corp Vectores lentivirales y su uso.
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
WO2006125962A2 (en) 2005-05-25 2006-11-30 Medigene Limited T cell receptors which specifically bind to vygfvracl-hla-a24
GB2442048B (en) 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
US9862927B2 (en) 2010-01-22 2018-01-09 Baylor Research Institute Dendritic cell vaccines
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
WO2011148194A1 (en) 2010-05-28 2011-12-01 Oxford Biomedica (Uk) Ltd Delivery of lentiviral vectors to the brain
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US8999937B2 (en) 2011-02-28 2015-04-07 Indiana University Research And Technology Corporation Glucocorticoid induced leucine zipper mimetics as therapeutic agents in multiple sclerosis
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
AU2012257377B2 (en) 2011-05-17 2017-09-07 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination
US20120295960A1 (en) 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
AU2012309830B2 (en) 2011-09-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage
EP3326467B1 (en) 2011-09-16 2020-03-11 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
US20150140019A1 (en) 2012-07-13 2015-05-21 The Trustees Of The University Of Pennsylvania Compositions and Methods for Regulating CAR T Cells
KR102499753B1 (ko) 2012-07-27 2023-02-16 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Ｔ 세포 수용체 조작
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CN113684185A (zh) 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
US11965892B2 (en) * 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
CA3060569A1 (en) * 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
EP4197552A1 (en) * 2018-03-12 2023-06-21 The Children's Hospital of Philadelphia Methods and compositions for use of tumor self-antigens in adoptive immunotherapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090130134A1 (en) 2005-02-07 2009-05-21 Veronique Pancre T CD4+ Epitopes of Type I and II Latency Antigens of the Epstein-Barr Virus, Which Can Be Recognized by the majority of individuals in the caucasian populations and applications thereof
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
US20170212984A1 (en) 2015-12-16 2017-07-27 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
JP2020518083A (ja) 2017-03-31 2020-06-18 ヤン、ペイ−ジア 免疫原性がん特異的エピトープのためのランク付けシステム

Also Published As

Publication number Publication date
US11183272B2 (en) 2021-11-23
MX2021007556A (es) 2021-09-10
PH12021551485A1 (en) 2022-04-11
CA3124457A1 (en) 2020-06-25
SG11202106678PA (en) 2021-07-29
IL284195A (en) 2021-08-31
JP2023071806A (ja) 2023-05-23
JP2024164839A (ja) 2024-11-27
JP7531009B2 (ja) 2024-08-08
JP2022518355A (ja) 2022-03-15
US20200279616A1 (en) 2020-09-03
KR20240091046A (ko) 2024-06-21
WO2020132586A1 (en) 2020-06-25
CN119864090A (zh) 2025-04-22
KR102670790B1 (ko) 2024-05-29
CN113474840A (zh) 2021-10-01
AU2019404547B2 (en) 2025-01-30
US20220199198A1 (en) 2022-06-23
EP3899954A1 (en) 2021-10-27
BR112021012278A2 (pt) 2021-12-14
CN113474840B (zh) 2024-12-17
EP3899954A4 (en) 2022-09-14
AU2019404547A1 (en) 2021-07-22
KR20210130705A (ko) 2021-11-01

Similar Documents

Publication Publication Date Title
JP7236543B2 (ja) Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム
Bear et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
Abelin et al. Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction
Joglekar et al. T cell antigen discovery via signaling and antigen-presenting bifunctional receptors
Bruno et al. High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform
Sharma et al. Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries
US20220033460A1 (en) Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19
US20260031189A1 (en) Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
CN118679522A (zh) 与mhc-肽靶标结合的抗原识别分子的脱靶预测方法
JP2024541968A (ja) 治療的介入のためにｍｈｃ関連抗原を同定するためのシステムおよび方法
US20260120799A1 (en) Methods and systems for prediction of hla epitopes
Liu et al. Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development
Marcilla et al. Comparative analysis of the endogenous peptidomes displayed by HLA-B* 27 and Mamu-B* 08: two MHC class I alleles associated with elite control of HIV/SIV infection
Flesch et al. Altered CD8+ T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F1 mice
US20250299771A1 (en) Systems and methods for generating chimeric major histocompatibility complex (mhc) molecules with desired peptide-binding specificities
RU2826261C2 (ru) Способ и системы для прогнозирования специфических для hla класса ii эпитопов и охарактеризации cd4+ t-клеток
Merkle et al. Probing the conformational dynamics of affinity-enhanced T cell receptor variants upon binding the peptide-bound major histocompatibility complex by Hydrogen/Deuterium Exchange mass spectrometry
HK40123046A (zh) 用於预测hla ii类特异性表位及表徵cd4+t细胞的方法和系统
HK40062113B (zh) 用於预测hla ii类特异性表位及表徵cd4+ t细胞的方法和系统
HK40062113A (en) Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
Gejman et al. Prospective identification of cross-reactive human peptide-MHC ligands for T cell receptor based therapies
Obermair et al. High resolution profiling of MHC-II peptide presentation capacity, by Mammalian Epitope Display, reveals SARS-CoV-2 targets for CD4 T cells and mechanisms of immune-escape

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221220

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230227

R150 Certificate of patent or registration of utility model

Ref document number: 7236543

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250